Replacing immunoassays with tryptic digestion-peptide immunoaffinity enrichment and LC-MS/MS
about
Mass spectrometry - an alternative in growth hormone measurementImmunocapture strategies in translational proteomics.Clinical review: improving the measurement of serum thyroglobulin with mass spectrometry.Rapid development of sensitive, high-throughput, quantitative and highly selective mass spectrometric targeted immunoassays for clinically important proteins in human plasma and serumPersonalized Proteomics: The Future of Precision Medicine.The use of selected reaction monitoring in quantitative proteomics.Clinical applications of capillary electrophoresis coupled to mass spectrometry in biomarker discovery: Focus on Bladder Cancer.Advances in the quantitation of therapeutic insulin analogues by LC-MS/MS.Colorectal cancer biomarker discovery and validation using LC-MS/MS-based proteomics in blood: truth or dare?Applications of low-flow LC-SRM for the analysis of large molecules in pharmaceutical R&D.Current trends in magnetic particle enrichment for mass spectrometry-based analysis of cardiovascular protein biomarkers.Strategies for improving sensitivity and selectivity for the quantitation of biotherapeutics in biological matrix using LC-MS/MS.Quantification of biopharmaceuticals and biomarkers in complex biological matrices: a comparison of liquid chromatography coupled to tandem mass spectrometry and ligand binding assays.Immunoaffinity techniques coupled to mass spectrometry for the analysis of human peptide hormones: advances and applications.Selected Reaction Monitoring Mass Spectrometry for Absolute Protein Quantification.A liquid chromatography-tandem mass spectrometry-based targeted proteomics approach for the assessment of transferrin receptor levels in breast cancer.Mass Spectrometry Applications for Toxicology.Stable Isotope Labeling by Amino acid in Vivo (SILAV): a new method to explore protein metabolism.A new mass spectrometry-based method for the quantification of histones in plasma from septic shock patients.Practical immunoaffinity-enrichment LC-MS for measuring protein kinetics of low-abundance proteinsLC-MS/MS of large molecules in a regulated bioanalytical environment - which acceptance criteria to apply?Quantitative measurements of GDF-8 using immunoaffinity LC-MS/MS.2D-LC-MS/MS to measure cleaved high-molecular-weight kininogen in human plasma as a biomarker for C1-INH-HAE.Quantitative LC/ESI-SRM/MS of antibody biopharmaceuticals: use of a homologous antibody as an internal standard and three-step method development.LC-MS/MS strategies for therapeutic antibodies and investigation into the quantitative impact of antidrug-antibodies.Reagent-free LC-MS/MS-based pharmacokinetic quantification of polyhistidine-tagged therapeutic proteins.Highly sensitive antibody-free μLC-MS/MS quantification of rhTRAIL in serum.A whole-molecule immunocapture LC-MS approach for the in vivo quantitation of biotherapeutics.Immunoaffinity-coupled MS: best of both technologies.Bioanalytical method validation considerations for LC-MS/MS assays of therapeutic proteins.
P2860
Q26865253-427BEC27-B3D2-4362-A114-15F3D6C5E167Q36519000-C68850FF-2894-4015-AE27-0C4725C29E97Q36736452-975360F7-B7B5-4336-9EFE-E6337478FD59Q37187946-F01F656C-CEF3-484E-8665-EC1B9556AF00Q37426540-B9E5BF73-6566-48C1-93BA-BD9A35760429Q38033244-E1C7079E-5736-4324-9839-F23CA9E45993Q38130892-D547BBE0-5E1E-422B-9137-CB485A49504EQ38167831-7DE08B49-F04D-40B3-9373-E67F455EC991Q38202166-0EB56782-8255-41A2-A49B-453D1CCD07D7Q38243346-EEF5ED4D-26ED-443B-B46F-B3DE91941717Q38364469-D107A247-E301-493A-8F25-53B189296209Q38379961-79A2A8AE-1554-4F64-98B7-48EBF532F345Q38500988-97D16970-707A-4FD5-BEA6-AE7AB764B8A2Q38649414-E50D9776-ADC0-429C-974B-EBD1FD96E6C1Q38839133-6583E1A2-AB4E-483F-AD10-EFEAED80EF5CQ39012698-D65FF076-1FDA-4A00-AD5D-185BD2405144Q39114251-E8CF1783-1BEA-42E1-B4D6-CDB98EF5EEADQ40495056-962FC77B-69E0-49B1-86A2-49A6070B3C68Q41630743-7C8A2B9E-5E83-4BD3-90B7-529B7DC29B90Q41781616-5B941BF7-C41B-4921-8D6E-66CFDD451AE2Q44315206-F51A3AC8-AB1F-475F-B1B4-E4B53558CBECQ46600197-E333EFED-6DF7-48B5-8353-32FF6ED8A020Q47180647-6EAA3AAF-D82B-49DB-85D0-043FAE331DDFQ48721182-49DAAB76-72B4-4910-B80F-6EE5DDC785F7Q48923909-975394F3-E425-4695-A889-FADDBF0925C9Q51184863-38780C6D-AA8A-42A0-AACC-12A5136F2895Q51373757-35286EEE-5D8B-41C2-82FF-F3DC186A3451Q51525919-45C7E8E8-513A-4BB4-9F56-5380CF041E92Q51652100-B14A1729-34A1-4C6D-B128-88A4EC12110DQ53642158-A1E0F639-A2D0-4167-88A3-8FA2C224A811
P2860
Replacing immunoassays with tryptic digestion-peptide immunoaffinity enrichment and LC-MS/MS
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Replacing immunoassays with tr ...... finity enrichment and LC-MS/MS
@en
type
label
Replacing immunoassays with tr ...... finity enrichment and LC-MS/MS
@en
prefLabel
Replacing immunoassays with tr ...... finity enrichment and LC-MS/MS
@en
P2860
P356
P1433
P1476
Replacing immunoassays with tr ...... finity enrichment and LC-MS/MS
@en
P2093
Jessica O Becker
P2860
P304
P356
10.4155/BIO.11.319
P577
2012-02-01T00:00:00Z